How much revenue does Alkem Laboratories make?

Alkem Laboratories reported 128.05 billion INR in revenue for fiscal year 2025, up 2.9% from 124.39 billion INR in fiscal year 2024. In Q2 2026 revenue was 40.01 billion INR.

Where does Alkem Laboratories make most of its revenue?

India: 71% of revenue by region in fiscal year 2025, followed by United States (19%).

What companies are similar to Alkem Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Aurobindo Pharma Limited (AUROPHARMA.NS), Lupin Limited (LUPIN.NS), Glenmark Pharmaceuticals Limited (GLENMARK.NS), Biocon Limited (BIOCON.NS).

Alkem Laboratories Limited (ALKEM.NS) Stock

About Alkem Laboratories Limited

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers biosimilars, active pharmaceutical ingredients, branded and trade generics, complex generics, and consumer wellness products in therapeutic areas comprising anti infec...

At a glance

Alkem Laboratories reported revenue of 128.05 billion INR for fiscal year 2025, up 2.9% from fiscal year 2024, and net income of 21.65 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 40.01 billion INR, up 17.2% from a year before. India was its largest region in fiscal year 2025, with 71% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.